Literature DB >> 17993846

Patient parameters and other radiation safety issues in 131I therapy for thyroid cancer treatment.

Abdalla N Al-Haj1, Charlie S Lagarde, Aida M Lobriguito.   

Abstract

Patients administered with a therapeutic dose of I for thyroid cancer treatment are potential sources of unacceptably high radiation exposure to other individuals, particularly the patient's immediate family members. Generally, patients are hospitalized until such time that the retained radioactivity in the body or the measured dose rate at 1 m from the patient's body surface fall to within acceptable levels. Patient release criteria are set to ensure that no individual shall be liable to receive exposures above the regulatory dose limit for the public or dose constraints for the patient's relatives or caregivers.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17993846     DOI: 10.1097/01.HP.0000270274.66246.7e

Source DB:  PubMed          Journal:  Health Phys        ISSN: 0017-9078            Impact factor:   1.316


  3 in total

1.  The study of external dose rate and retained body activity of patients receiving 131I therapy for differentiated thyroid carcinoma.

Authors:  Haiying Zhang; Ling Jiao; Songye Cui; Liang Wang; Jian Tan; Guizhi Zhang; Yajing He; Shuzhou Ruan; Saijun Fan; Wenyi Zhang
Journal:  Int J Environ Res Public Health       Date:  2014-10-21       Impact factor: 3.390

2.  Do Current Radiation Safety Guidelines allow the Safe Release of a Thyroid Cancer Patient after High-dose Radioiodine Therapy? An Indian Perspective.

Authors:  Subhash Chand Kheruka; Nilesh Shankar; Manish Ora; Sanjay Gambhir
Journal:  Indian J Nucl Med       Date:  2021-06-21

3.  Occupational exposure and radiobiological risk from thyroid radioiodine therapy in Saudi Arabia.

Authors:  H I Al-Mohammed; A Sulieman; Fareed H Mayhoub; Hassan Salah; Celestino Lagarde; M Alkhorayef; Ali Aldhebaib; C Kappas; D A Bradley
Journal:  Sci Rep       Date:  2021-07-15       Impact factor: 4.379

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.